Medial Gastrocnemius Muscle Properties of Children With Cerebral Palsy After Different Tone Treatments: A Pilot Study.

Christiana J Raymond-Pope, Daniel B Hoffman, Rachael M Bloxsom, Sarah M Greising, Tom F Novacheck, Elizabeth R Boyer
Author Information
  1. Christiana J Raymond-Pope: From the School of Kinesiology (CJR-P, DBH, RMB, SMG) and Department of Orthopedic Surgery (TFN, ERB), University of Minnesota, Minneapolis, Minnesota; and Gillette Children's Specialty Healthcare, St. Paul, Minnesota (TFN, ERB).

Abstract

OBJECTIVE: Spasticity in children with cerebral palsy can be managed by a spectrum of approaches, from conservative therapy, to temporary botulinum toxin A injections, to permanent transection of sensory nerves with a selective dorsal rhizotomy. This pilot study investigated whether these three tone management approaches are associated with histological and biochemical properties of the medial gastrocnemius.
DESIGN: A convenience sample of children with cerebral palsy undergoing gastrocnemius lengthening surgery was enrolled. Intraoperative biopsies were obtained from three individuals (one each: minimal tone treatment; frequent gastrocnemius botulinum toxin A injections; previous selective dorsal rhizotomy). All individuals had plantarflexor contractures, weakness, and impaired motor control before the biopsy.
RESULTS: Differences between participants were observed for muscle fiber cross-sectional area, fiber type, lipid content, satellite cell density, and centrally located nuclei. The most pronounced difference was the abundance of centrally located nuclei in the botulinum toxin A participants (52%) compared with the others (3-5%). Capillary density, collagen area and content, and muscle protein content were similar across participants.
CONCLUSIONS: Several muscle properties seemed to deviate from reported norms, although age- and muscle-specific references are sparse. Prospective studies are necessary to distinguish cause and effect and to refine the risks and benefits of these treatment options.

References

  1. Dev Med Child Neurol. 2010 Sep;52(9):794-804 [PMID: 20477832]
  2. Dev Med Child Neurol. 2013 Mar;55(3):264-70 [PMID: 23210987]
  3. J Neurol Sci. 2007 Feb 15;253(1-2):25-33 [PMID: 17196619]
  4. Muscle Nerve. 2018 Aug;58(2):277-285 [PMID: 29572878]
  5. J Neurol Sci. 1989 Dec;94(1-3):29-40 [PMID: 2614471]
  6. Front Physiol. 2013 Dec 12;4:363 [PMID: 24376424]
  7. Connect Tissue Res. 2021 May;62(3):287-298 [PMID: 31779492]
  8. Anat Rec. 2000 Dec 1;260(4):351-8 [PMID: 11074399]
  9. Dev Med Child Neurol. 2015 May;57(5):484-90 [PMID: 25523506]
  10. JBJS Rev. 2019 Aug;7(8):e4 [PMID: 31415277]
  11. Arch Phys Med Rehabil. 2007 Sep;88(9):1114-20 [PMID: 17826455]
  12. J Gerontol. 1992 May;47(3):B71-6 [PMID: 1573181]
  13. J Orthop Res. 1994 Nov;12(6):758-68 [PMID: 7983551]
  14. Int J Biochem Cell Biol. 2013 Oct;45(10):2191-9 [PMID: 23702032]
  15. J Orthop Res. 2015 Jul;33(7):1039-45 [PMID: 25732238]
  16. Connect Tissue Res. 2022 Mar;63(2):124-137 [PMID: 33535825]
  17. Gait Posture. 2017 May;54:119-126 [PMID: 28288332]
  18. J Neurol Sci. 1988 Dec;88(1-3):303-13 [PMID: 3225628]
  19. J Physiol. 2011 May 15;589(Pt 10):2625-39 [PMID: 21486759]
  20. Cell Tissue Res. 2010 Jun;340(3):541-8 [PMID: 20467789]
  21. Front Hum Neurosci. 2022 Jun 03;16:846205 [PMID: 35721346]
  22. Dev Med Child Neurol. 2022 Mar;64(3):379-386 [PMID: 34534360]
  23. Dev Med Child Neurol. 2022 May;64(5):561-568 [PMID: 34755903]
  24. Gait Posture. 2012 May;36(1):113-9 [PMID: 22386624]
  25. Muscle Nerve. 2016 Mar;53(3):407-14 [PMID: 26154631]
  26. J Pediatr Orthop B. 2005 Jul;14(4):269-73 [PMID: 15931031]
  27. Dev Med Child Neurol. 2010 Mar;52(3):264-9 [PMID: 20089048]
  28. Int J Mol Sci. 2020 Jun 02;21(11): [PMID: 32498422]
  29. Nat Methods. 2012 Jul;9(7):671-5 [PMID: 22930834]
  30. Age (Dordr). 2014 Apr;36(2):545-7 [PMID: 24122288]

Grants

  1. T32 AR050938/NIAMS NIH HHS

MeSH Term

Child
Humans
Botulinum Toxins, Type A
Pilot Projects
Neuromuscular Agents
Prospective Studies
Cerebral Palsy
Treatment Outcome
Muscle, Skeletal
Muscle Spasticity

Chemicals

Botulinum Toxins, Type A
Neuromuscular Agents

Word Cloud

Created with Highcharts 10.0.0botulinumtoxingastrocnemiusparticipantsmusclecontentchildrencerebralpalsyapproachesinjectionsselectivedorsalrhizotomythreetonepropertiesindividualstreatmentfiberareadensitycentrallylocatednucleiOBJECTIVE:SpasticitycanmanagedspectrumconservativetherapytemporarypermanenttransectionsensorynervespilotstudyinvestigatedwhethermanagementassociatedhistologicalbiochemicalmedialDESIGN:conveniencesampleundergoinglengtheningsurgeryenrolledIntraoperativebiopsiesobtainedoneeach:minimalfrequentpreviousplantarflexorcontracturesweaknessimpairedmotorcontrolbiopsyRESULTS:Differencesobservedcross-sectionaltypelipidsatellitecellpronounceddifferenceabundance52%comparedothers3-5%CapillarycollagenproteinsimilaracrossCONCLUSIONS:Severalseemeddeviatereportednormsalthoughage-muscle-specificreferencessparseProspectivestudiesnecessarydistinguishcauseeffectrefinerisksbenefitsoptionsMedialGastrocnemiusMusclePropertiesChildrenCerebralPalsyDifferentToneTreatments:PilotStudy

Similar Articles

Cited By